River Wealth Advisors LLC Has $1.56 Million Stake in Elevance Health, Inc. $ELV

River Wealth Advisors LLC lowered its holdings in Elevance Health, Inc. (NYSE:ELV) by 59.5% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,818 shares of the company’s stock after selling 7,090 shares during the period. River Wealth Advisors LLC’s holdings in Elevance Health were worth $1,557,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the business. Vermillion & White Wealth Management Group LLC grew its position in Elevance Health by 94.9% during the second quarter. Vermillion & White Wealth Management Group LLC now owns 76 shares of the company’s stock worth $30,000 after buying an additional 37 shares in the last quarter. BOK Financial Private Wealth Inc. bought a new stake in shares of Elevance Health during the 2nd quarter valued at $32,000. Physician Wealth Advisors Inc. grew its holdings in shares of Elevance Health by 331.6% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company’s stock worth $26,000 after purchasing an additional 63 shares in the last quarter. Rossby Financial LCC increased its position in shares of Elevance Health by 110.0% in the third quarter. Rossby Financial LCC now owns 84 shares of the company’s stock worth $28,000 after purchasing an additional 44 shares during the period. Finally, Activest Wealth Management raised its stake in Elevance Health by 66.7% in the third quarter. Activest Wealth Management now owns 85 shares of the company’s stock valued at $27,000 after purchasing an additional 34 shares in the last quarter. 89.24% of the stock is owned by institutional investors.

Elevance Health Price Performance

Shares of ELV opened at $320.65 on Friday. The business has a 50-day moving average of $350.23 and a 200-day moving average of $335.70. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.54 and a quick ratio of 1.54. The company has a market capitalization of $70.77 billion, a price-to-earnings ratio of 12.76, a price-to-earnings-growth ratio of 1.77 and a beta of 0.50. Elevance Health, Inc. has a 1 year low of $273.71 and a 1 year high of $458.75.

Elevance Health (NYSE:ELV) last released its earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share for the quarter, beating analysts’ consensus estimates of $3.10 by $0.23. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. The business had revenue of $49.31 billion during the quarter, compared to the consensus estimate of $49.52 billion. During the same quarter in the prior year, the firm posted $3.84 EPS. The company’s revenue for the quarter was up 9.6% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 25.500- EPS. As a group, equities research analysts anticipate that Elevance Health, Inc. will post 33.96 earnings per share for the current year.

Elevance Health Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Tuesday, March 10th will be paid a dividend of $1.72 per share. This is a boost from Elevance Health’s previous quarterly dividend of $1.71. This represents a $6.88 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date of this dividend is Tuesday, March 10th. Elevance Health’s payout ratio is 27.23%.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on ELV shares. Weiss Ratings downgraded shares of Elevance Health from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, February 2nd. Leerink Partners increased their price target on shares of Elevance Health from $350.00 to $357.00 and gave the stock a “market perform” rating in a research report on Thursday, January 29th. Morgan Stanley decreased their price objective on shares of Elevance Health from $359.00 to $352.00 and set an “equal weight” rating on the stock in a research note on Wednesday, December 17th. Robert W. Baird upped their target price on Elevance Health from $297.00 to $340.00 and gave the stock a “neutral” rating in a research note on Thursday, December 11th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $332.00 price target on shares of Elevance Health in a research note on Thursday, January 29th. Twelve equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Elevance Health presently has a consensus rating of “Moderate Buy” and a consensus target price of $390.55.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.